%Responders to BEVACIZUMAB in the cohort (WORLD):
by Thymidine Incorporation (95% CI): %2.1127 (0.93897,3.5211)
by IL-2 ELISpot (95% CI): %0 (0,0)
by Combined Thymidine Incorporation & IL-2 ELISpot (95% CI): %0 (0,0)
--
%Similarity between Thymidine Incorporation & IL-2 ELISpot predictions (95% CI): %97.8754 (96.7069,99.0424)
